Activin RIB 詳細
Molecule Name
Transforming growth factor beta receptor 1
分子の別称
ACVR1b,ALK4,ACVRLK4,ACTR-IB,SKR2
Drug Development Progress
治験薬の数7
市販薬剤の数0
研究＆開発段階Phase 3 Clinical
ターゲットの別称
EC 2.7.11，TGF-beta type I receptor，Serine/threonine-protein kinase receptor R4，TGFBR1，Activin A receptor type II-like protein kinase of 53kD，Transforming Growth Factor Beta Receptor 1，Transforming Growth Factor-Beta Receptor Type I，Activin A Receptor Type II-Like Kinase， 53kDa，Activin Receptor-Like Kinase 5，TGFR-1，ALK-5，ALK5，SKR4，Mutant Transforming Growth Factor Beta Receptor I，TGF-Beta Receptor Type-1，TGF-Beta Receptor Type I，EC 2.7.11.30，ACVRLK4，LDS1A，LDS2A，AAT5，LDS1，TBRI，ESS1，MSSE，TbetaR-I，Transforming Growth Factor Beta Receptor I，Multiple Self-Healing Squamous Epithelioma，TBR-I，Receptor， Transforming Growth Factor-beta Type I，EC:2.7.11.30
バックグランド
Activin receptor type-1B (ACVR1B) is also known as Activin receptor-like kinase 4 (ALK-4), Serine/threonine-protein kinase receptor R2 (SKR2), which belongs to the protein kinase superfamily, TKL Ser/Thr protein kinase family and TGFB receptor subfamily. ACVR1B contains one GS domain and one protein kinase domain. The catalytic activity of ACVR1B is “ATP + [receptor-protein] = ADP + [receptor-protein] phosphate”. ACVR1B acts as a transducer of activin or activin like ligands (e.g., inhibin) signals. Activin binds to either ACVR2A or ACVR2B and then forms a complex with ACVR1B. These go on to recruit the R-SMADs SMAD2 or SMAD3. ACVR1B also transduces signals of nodal, GDF-1, and Vg1.
Activin RIB 製品リスト
You Have Viewed 0 Of 0 Results
治験薬に関する情報
| 英語名 | 研究コード | 研究開発ステージ | 会社 | 適応症 | 臨床試験 |
|---|---|---|---|---|---|
| Galunisertib | LY-2157299 | Phase 3 Clinical | Eli Lilly And Company | Amyotrophic Lateral Sclerosis; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Glioblastoma; Glioma; Liver Neoplasms; Metastatic breast cancer; Myelodysplastic Syndromes; Nasopharyngeal Carcinoma; Neoplasm Metastasis; Neoplasms; Pancreatic Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Rectal Neoplasms; Solid tumours; Triple Negative Breast Neoplasms | 詳細 |
| GF-101 | GFH-018; GF-101; GFH018 | Phase 2 Clinical | Genfleet Therapeutics (Shanghai) Co Ltd | Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Liver Neoplasms; Pancreatic Neoplasms; Solid tumours | 詳細 |
| Tosposertib phosphate | TU-2218; NCE401; NCE-401 | Phase 2 Clinical | TiumBio Co Ltd | Idiopathic Pulmonary Fibrosis; Solid tumours | 詳細 |
| Ontunisertib | ORG-129; AGMB-129 | Phase 2 Clinical | Origo Biopharma Sociedad Litmitada | Crohn Disease | 詳細 |
| TRK-250 | TRK-250; BNC-1021 | Phase 1 Clinical | Bonac Corp | Idiopathic Pulmonary Fibrosis | 詳細 |
| Oxinseti | SH-3051 | Phase 1 Clinical | Nanjing Sanhome Pharmaceutical Co Ltd | Liver Neoplasms; Solid tumours | 詳細 |
| AGMB-447 | AGMB-447; ORG-447 | Phase 1 Clinical | AgomAb Therapeutics NV | Idiopathic Pulmonary Fibrosis | 詳細 |